Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial

Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial

BackgroundWe aimed to evaluate the efficacy, safety, and immunogenicity of a SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012 given as the booster in immunized but SARS-CoV-2 infection-free adults in China.MethodsThis is a single-center, randomized, double-blind, placebo-controlled phase 3 clinical t...

Full description

Bibliographic Details
Main Authors: Huan Zhou, Hui Zheng, Yucai Peng, Yue Su, Xuya Yu, Weixiao Wang, Simin Li, Yuzhou Ding, Shiping Jiao, Ying Wang, Xingyu Zhu, Liping Luo, Ziyong Dong, Lu Liu, Fan Zhang, Qiang Wu, Jingxin Li, Fengcai Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Immunology
Subjects:
COVID-19
mRNA vaccine
booster dose
heterologous immunization
inactivated vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1407826/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1407826/full

Similar Items